Abstract
It has been claimed that long-term prednisone treatment ameliorates the course of children with mesangiocapillary glomerulonephritis (MCGN). The International Study of Kidney Disease in Children conducted a randomized, double-blinded, placebo-controlled clinical trial in 80 children with idiopathic MCGN, including 42 patients with type I disease, 14 with type II disease, 17 with type III disease, and 7 with nontypable disease. Criteria for admission included heavy proteinuria and a glomerular filtration rate of greater than or equal to 70 ml/min per 1.73 m2. Prednisone or lactose, 40 mg/m2, was given every other day as a single morning dose. The mean duration of treatment was 41 months, renal failure being the most common reason for termination of therapy. Treatment failure was defined as an increase from baseline of 30% or more in serum creatinine, or more than 35 μmol/l. Overall, treatment failure occurred in 55% of patients treated with lactose, compared with 40% in the prednisone group. Life-table analysis showed a renal survival rate (i.e., stable renal function) at 130 months of 61% among patients receiving prednisone and 12% among patients receiving lactose (P=0.07). Of patients with type I or III MCGN, 33% treated with prednisone were treatment failures, compared with 58% in the lactose group. Long-term treatment with prednisone appears to improve the outcome of children with MCGN.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Habib R, Kleinknecht C, Gubler MC, Levy M (1973) Idiopathic membranoproliferative glomerulonephritis in children. Report of 105 cases. Clin Nephrol 1: 194–214
Ogg CS, Cameron JS, White RHR (1968) The C'3 component of complement in patients with heavy proteinuria. Lancet II: 78–81
International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Int 13: 159–165
Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J (1983) Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74: 175–192
Davis AE, Schneeberger EE, Grupe WE, McCluskey RT (1978) Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease in children (DDD). Clin Nephrol 9: 184–193
Habib R, Gubler MC, Loirat C, Maiz HB, Levy M (1975) Dense deposit disease: a variant of membranoproliferative glomerulonephritis. Kidney Int 7: 204–215
Strife CF, McEnery PT, McAdams AJ, West CD (1977) Membranoproliferative glomerulonephritis with disruption of the glomerular basement membrane. Clin Nephrol 7: 65–72
Galle P, Mahieu P (1975) Electron dense alteration of kidney basement membranes: a renal lesion specific of a systemic disease. Am J Med 58: 749–764
Lamb V, Tisher CC, McCoy RC, Robinson RR (1977) Membranoproliferative glomerulonephritis with dense intramembranous alterations. A clinicopathologic study. Lab Invest 36: 607–617
West DC (1981) Idiopathic membranoproliferative glomerulonephritis. In: Zurukzoglu W, Papadimitriou M, Pyrpasotoulos M, Sion M, Zamboulis C (eds) Proceedings of the 8th Congress of Nephrology (1981). Advances in basic and clinical nephrology. Karger, Athens, p 283
Donadio JV Jr, Anderson CF, Mitchell JC III, Holley KE, Ilstrup DM, Fuster V, Chesboro JH (1984) Membranoproliferative glomerulonephritis: a prospective clinical trial of platelet inhibitor therapy. N Engl J Med 310: 1421–1426
McEnery PT, McAdams AJ, West CD (1980) Membranoproliferative glomerulonephritis: improved survival with alternate day prednisone therapy. Clin Nephrol 13: 117–124
Kincaid-Smith P (1973) The natural history and treatment of mesangiocapillary glomerulonephritis. In: Kincaid-Smith P (ed) Glomerulonephritis, morphology, natural history and treatment. I. Wiley, New York, p 591
Chapman SJ, Cameron JS, Chantler C, Turner D (1980) Treatment of mesangiocapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. Arch Dis Child 55: 446–451
Tiller DJ, Clarkson AR, Mathew T, Thompson N, Row G, Lauer C, Hobbs J, Seymour A (1981) A prospective randomized trial in the use of cyclophosphamide, dipyridamole, and warfarin in membranous and mesangiocapillary glomerulonephritis. In: Zurukzoglu W, Papadimitriou M, Pyrpasotoulos M, Sion M, Zamboulis C (eds) Proceedings of the 8th International Congress of Nephrology (1981). Advances in basic and clinical nephrology. Karger, Athens, p 345
McEnery PT, McAdams AJ, West CD (1985) The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore) 64: 401–423
Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U (1983) Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 75: 920–927
Warady BA, Guggenheim SJ, Sedman A, Lum GM (1985) Prednisone therapy of membranoproliferative glomerulonephritis in children. J Pediatr 107: 702–707
Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN (1985) Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 27: 436–441
Donadio JV, Offord KP (1989) Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on lifetable analysis. Am J Kidney Dis 14: 445–451
Churg J, Habib R, White RHR (1970) Pathology of the nephrotic syndrome in children. A report for the International Study of Kidney Disease in Children. Lancet I: 1299–1302
Churg J, Sobin LH (1982) Diffuse mesangiocapillary glomerulonephritis. In: Renal disease. Classification and atlas of glomerular diseases. Igaku-Shoin, Tokyo, p 83
SAS/STAT software: the PHREG procedure (preliminary edition documentation) (1991) SAS Institute, Cary, North Carolina
Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
Gross AJ, Clark VA (1975) Survival distributions: reliability applications in the biomedical sciences. Wiley, New York, p 45
Kalbfleisch JD, Prentice RL (1980) The Statistical analysis of failure time data. Wiley, New York
Jackson EX, McAdams AJ, Strife CF, Forristal J, Welch TR, West CD (1987) Differences between membranoproliferative glomerulonephritis types I and III in clinical presentation, glomerular morphology, and complement perturbation. Am J Kidney Dis 9: 115–120
White RHR (1992) Mesangiocapillary glomerulonephritis. In: Edelmann CM Jr, Bernstein J, Meadow SR, Spitzer A, Travis L (eds) Pediatric kidney disease, 2nd edn. Little Brown, Boston, pp 1307–1324
Donadio JV Jr, Offord KP (1989) Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on lifetable analysis. Am J Kidney Dis 6: 445–451
McEnery PT (1990) Membranoproliferative glomerulonephritis: the Cincinnati experience — cumulative renal survival from 1957 to 1989. J Pediatr 116: S110-S114
Strife CF, Jackson EC, McAdams AJ (1984) Type III membranoproliferative glomerulonephritis: long-term clinical and morphologic evaluation. Clin Nephrol 21: 323–334
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tarshish, P., Bernstein, J., Tobin, J.N. et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone —a report of The International Study of Kidney Disease in Children. Pediatr Nephrol 6, 123–130 (1992). https://doi.org/10.1007/BF00866289
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866289